Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.6% – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) fell 4.6% during trading on Monday . The stock traded as low as $16.88 and last traded at $16.6120. Approximately 4,994 shares changed hands during trading, a decline of 27% from the average session volume of 6,831 shares. The stock had previously closed at $17.42.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Finally, B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Trading Down 3.9%

The firm’s 50 day simple moving average is $18.39 and its 200 day simple moving average is $22.04. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors have recently added to or reduced their stakes in the business. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the third quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.